Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.
First Department of Medicine, Semmelweis University, Budapest, Hungary.
Zsuzsanna
Z
Vegh
Zsuzsanna
Z
Kurti
Peter L
PL
Lakatos
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D057915:Drug Substitution; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D007413:Intestinal Mucosa; D012074:Remission Induction; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D000069285:Infliximab